| Document |
Document Title |
|
WO/2012/059874 |
The present disclosure is in relation to a herbal cleansing composition comprising extracts from five plants namely Emblica officinalis, Terminalia chebula, Terminalia bellerica, Glycyrrhiza glabra and Azadiracta indica. Further, the pre...
|
|
WO/2012/060734 |
The invention relates to organic chemistry, specifically to peptide compounds. What is claimed is: a modified N-protected dipeptide of general formula (I), where X = H, Na or K, with a molecular mass of 417.5 - 456.5. The compound inhibi...
|
|
WO/2012/059001 |
Disclosed are imidazole derivatives as represented by formula (I), and preparation method and use thereof. The compounds can inhibit cyclooxygenase and treat diseases mediated by cyclooxygenase.
|
|
WO/2012/061576 |
Crystalline forms of (S) - 2 -amino- 3 - (4 - (2 -amino- 6 - ( (R) - 1 - (4 - chloro- 2 - (3 -methyl - lH-pyrazol - 1 -yl) phenyl) - 2, 2, 2 - trifluoroethoxy) pyrimidin - 4 -yl) phenyl) propanoic acid and salts thereof are disclosed. Ph...
|
|
WO/2012/059724 |
The present invention concerns a solid formulation for oral administration as a solid comprising polyethylene glycol and a further solid such as mannitol. The formulation may be used to prevent gastrointestinal disorders such as constipa...
|
|
WO/2012/058868 |
Hepatocyte-like cells which express a Hnf polypeptide and a Foxa polypeptide, the method of generating the cells and the uses of the cells are provided.
|
|
WO/2012/059090 |
The invention relates to the use of etacrynic acid of the formula (I) for the prophylaxis and treatment of food sensitivity disorders, food intolerances and skin diseases and in particular coeliac disease, and to compositions comprising ...
|
|
WO/2012/060312 |
The present invention inhibits biofilm formation by Streptococcus mutans and treats tooth decay by using a vegetable lactic acid bacterium belonging to the genus Enterococcus, said vegetable lactic acid bacterium being isolated from rice...
|
|
WO/2012/058769 |
A method of treating mucosal inflammation associated with a pathological condition in a mammal is provided. The method comprises the step of inhibiting 5-HT signaling at a target site in order to block 5-HT7 receptor function.
|
|
WO/2012/057670 |
A method of assessing the risk of a person developing dental caries under controlled conditions of oral hygiene and sugar intake comprises determining, in a sample of saliva acidic proline-rich proteins (PRP) procured from said person, t...
|
|
WO/2012/055015 |
A method for treating an ATP analog-induced side effect in a subject comprises administering an effective amount of an adenosine receptor antagonist to the subject. A method for treating cancer in a subject comprises administering a nucl...
|
|
WO/2012/058545 |
The present invention is directed to a method of analyzing and establishing a proper dosage size in ingestible films for providing a more precise dosage delivery of an active ingredient.
|
|
WO/2012/058664 |
Presented herein are methods for treating diarrhea by administering to a patient in need thereof, an inhibitor of chloride-ion transport in an amount sufficient to treat diarrhea. Treatment of diarrhea includes the treatment of the diarr...
|
|
WO/2012/056976 |
Provided is a novel compound capable of inhibiting cardiac adenylate cyclase. The compound is a compound represented by formula (I) or a pharmaceutically acceptable salt, ester or solvate thereof. (In the formula, R1, R2 and R3 independe...
|
|
WO/2012/057417 |
The present invention relates to a composition containing Okamejei kenojei extract, and more particularly, to a composition which contains Okamejei kenojei extract as an active for treating skin diseases such as acne, treating gray hair ...
|
|
WO/2012/052060 |
The present invention relates to a method to increase the growth velocity of a human infant, said method comprising the enteral administration to said infant of recombinant human bile-salt- stimulated lipase (rhBSSL). Such method has par...
|
|
WO/2012/053758 |
The present invention relates to a pharmaceutical composition for treating or preventing alcoholic liver diseases, containing cilostazol as an active ingredient. Particularly, cilostazol concentration-dependently inhibits the expression ...
|
|
WO/2012/054376 |
A composition containing a plurality of water-soluble nanoclusters ranging from 2 nm to 500 nm in diameter. Each of the nanoclusters contains one or more metal cations, one or more anions, and one or more water-soluble ligands. Also disc...
|
|
WO/2012/052463 |
The present invention relates to the field of nutrition; in particular to the prevention and/or treatment of malnutrition. One embodiment of the present invention relates to a nutritional composition enriched in cysteine for use in the t...
|
|
WO/2012/054530 |
Provided herein are methods for treating conditions associated with a chemosensory receptor, including diabetes, obesity, and other metabolic diseases, disorders or conditions by administering a composition comprising a chemosensory rece...
|
|
WO/2012/054527 |
Provided herein are methods for treating conditions associated with a chemosensory receptor, including diabetes, obesity, and other metabolic diseases, disorders or conditions by administering a composition comprising a chemosensory rece...
|
|
WO/2012/052059 |
The present invention relates to a method to increase the absorption by a human infant of at least one unsaturated fatty acid, said method comprising the enteral administration to said infant of recombinant human bile-salt-stimulated lip...
|
|
WO/2012/054535 |
The invention relates to classes of pharmaceutically-active heterocyclic compounds and pharmaceutically acceptable salts, and hydrates thereof, and compositions comprising the same. The invention also relates to methods for treating or p...
|
|
WO/2012/054528 |
Provided herein are methods for treating conditions associated with a chemosensory receptor, including diabetes, obesity, and other metabolic diseases, disorders or conditions by administering a composition comprising a chemosensory rece...
|
|
WO/2012/052918 |
The invention relates to the use of mexiprostil in the treatment and/or prevention of inflammatory bowel disease and of irritable bowel syndrome, to the combinations of mexiprostil with other drugs, and also to a novel method for the syn...
|
|
WO/2012/050589 |
Provided herein are methods of treating gout, treating hyperuricemia, lowering serum uric acid, or the like with compounds of formula (I) have the following structure Further, provided herein are compositions comprising a compound of for...
|
|
WO/2012/050922 |
Gastric retentive dosage forms for sustained reiease of acamprosate are described which may allow once- or twice-daily dosing for both acute and long-term treatment of a disorder including alcohol dependence, tinnitus, sleep apnea, Parki...
|
|
WO/2012/048470 |
Small molecular ribonucleic acid (RNA) complexes are provided, which consist of small molecular RNAs extracted through isolating and purifying big molecular RNAs isolated from mammalian internal organs and then artificially degrading the...
|
|
WO/2012/050025 |
[Problem] To provide a medical adsorbent for oral administration that has excellent adsorption capacity and selective adsorption of toxins that are to be removed, even at low doses, and that is economical and minimizes environmental impa...
|
|
WO/2012/050184 |
The purpose of the present invention is to provide a pharmaceutical composition which comprises a medicinal agent and a collagen and has good handleability and sustained release properties. The purpose is achieved by a sustained-release ...
|
|
WO/2012/049503 |
The invention provides a material derived from algae (e.g. of the genus Chlorella) for the prevention or amelioration of plant-induced enteritis in fish. The algae- derived material is preferably intact or ruptured cells of and/or a cell...
|
|
WO/2012/049366 |
The present invention relates to a combined norovirus and rotavirus vaccine for prevention of norovirus and rotavirus infection and/orviral-induced diarrheal and vomiting dis- easesin man. More specifically, the invention comprises a met...
|
|
WO/2012/050151 |
Provided is a compound or a pharmaceutically acceptable salt thereof represented by general formula (I) which has an excellent blood glucose-lowering effect and protective effect on β cells or the pancreas, and also provided is a pharma...
|
|
WO/2012/045115 |
The present invention provides methods and compositions useful in the field of medicine, and particularly in the treatment of inflammatory disorders. More particularly, the invention relates to the use of methods and compositions for the...
|
|
WO/2012/048099 |
The invention provides nanoparticle-loaded cells and compositions useful for improved imaging and therapy, for example radio-therapy. The invention also provides methods of manufacture of nanoparticle-loaded cells, methods of administeri...
|
|
WO/2012/048093 |
The present invention provides preparations of MSCs with important therapeutic potential. The MSC cells are non-primary cells with an antigen profile comprising less than about 1.25% CD45+ cells (or less than about 0.75% CD45+), at least...
|
|
WO/2012/047826 |
The present invention provides methods for treating a disease or condition by administering to a subject at a frequency of more than 24 hours between doses, compositions and formulations of compounds having formula (I), and pharmaceutica...
|
|
WO/2012/048043 |
Disclosed herein are processes for making L-ornithine phenyl acetate. The process may include, for example, intermixing a halide salt of L-ornithine with silver phenyl acetate. The process may also include forming a phenyl acetate salt i...
|
|
WO/2012/045801 |
Lactoferrin-based complex coacervate inducing delayed protein digestion and modified peptide profile for improving metabolic responses, gut inflammatory response, satiety and food intake in humans, in association with an increase in GLP-...
|
|
WO/2012/047225 |
|
|
WO/2012/043838 |
The purpose of the present invention is to provide a highly safe drug which can effectively inhibit hepatitis C virus infection per se so as to prevent inflammation, differing from symptomatic treatments whereby various types of inflamma...
|
|
WO/2012/040915 |
A Chinese medicinal composition for treating stomach pain of hepatogastric stagnated heat type comprises the following materials (in weight parts): Herba Taraxaci Mongolici (1-30), Radix Paeoniae Rubra (1-30), Rhizoma Pinelliae Praeparat...
|
|
WO/2012/042349 |
A dental care preparation in a form of a toothpaste or tooth gel dentifrice includes an antimicrobial amount of at least one antimicrobial N-methylol transfer agent, and at least one of a fluoride compound or a source of fluoride ions.
|
|
WO/2012/043533 |
The purpose of the present invention is to provide a novel antihuman CCR7 antibody which is useful as a therapeutic agent for tissue fibrosis or cancer, a medicinal composition which comprises the antihuman CCR7 antibody, and so on. Prov...
|
|
WO/2012/043900 |
The present invention relates to a pharmaceutical composition containing a quinoline derivative, a stereoisomer thereof, a pharmaceutically acceptable salt thereof, or a hydrate or solvate thereof. The pharmaceutical composition improves...
|
|
WO/2012/043445 |
The purpose of the present invention is to find a therapeutic and/or prophylactic agent for gastrointestinal disorders and so on, said agent having an excellent activity and a high safety. A compound represented by general formula (I) or...
|
|
WO/2012/043743 |
The present invention provides an anti-bacterial composition containing rice malt or an extract of the rice malt, as a novel anti-bacterial technique. This composition may additionally contain a fermentation raw material for producing th...
|
|
WO/2012/038937 |
A 1:1:1 aprepitant L-proline H20 composition and a 1:1:1 aprepitant L-proline H20 cocrystal are disclosed as well as pharmaceutical compositions containing a 1:1:1 aprepitant L-prolirse H20 composition or cocrystai and a pharmaceutically...
|
|
WO/2012/037778 |
The present invention provides a polypeptide TF1 for inhibiting type-2 Shiga-toxin activity, an encoding gene for same and use thereof. The present polypeptide is named TF1 (also known as P1); its amino acid sequence is shown in SEQ ID N...
|
|
WO/2012/039639 |
The invention relates to bioengineering, and the foods and pharmaceutical industries. The composition for normalizing microflora and purifying an organism from toxins comprises at least one insoluble enterosorbent, at least one prebiotic...
|
